WASHINGTON, DC (February 6, 2020) —The Association for Accessible Medicines (AAM) announced the election of its 2020 Board of Directors and Officers today.
Mr. Alok Sonig, CEO – US Generics and Global Head – Generics R&D & Biosimilars, Lupin Inc. is the 2020 AAM Chair of the Board. AAM also named Ms. Carol Lynch, President, Sandoz US and Head of North America, Vice Chair of the Board and Mr. Brian Hoffmann, President US Generics Division, Hikma, as Treasurer.
Generic drugs saved the U.S. health system $293 billion in 2018, according to the Generic Drug Access & Savings in the U.S. report compiled by IQVIA on behalf of AAM.
The 2020 AAM Board of Directors includes:
- 3M Health Care Business
Aaron Mann, Vice President & General Manager
- Accord Healthcare, Inc.
Gerald Price, Chief Executive Officer
- American Regent
Harsher Singh, Vice President & Chief Commercial Officer
- Amneal Pharmaceuticals Inc.
Steve Manzano, Senior Vice President, General Counsel & Corporate Secretary
- Apotex Corporation
Peter Hardwick, Chief Commercial Officer
- Aurobindo Pharma USA, Inc.
Hunter Murdock, Vice President & General Counsel
- Cipla USA
Arunesh Verma, Chief Executive Officer
- Dr. Reddy's Laboratories, Inc.
Vanessa Brill, Vice President & Regional General Counsel, the Americas
- Fresenius Kabi USA
John Ducker, President & Chief Executive Officer
- Glenmark Pharmaceuticals, Inc. USA
Robert Matsuk, President North America
- Greenstone LLC, a subsidiary of Pfizer
Andrew Callos, General Manager North America, Upjohn (A Division of Pfizer)
- Hikma Pharmaceuticals USA
Brian Hoffmann, President US Generics Division
- Jubilant Cadista Pharmaceuticals, Inc.
Terrence Fullem, President
- Lupin Inc.
Alok Sonig, CEO, US Generics and Global Head Generics R&D & Biosimilars
- Mallinckrodt Specialty Generics
Spiro Gavaris, President, Specialty Generics
- Mayne Pharma Group Limited
Daniel Moore, Executive Vice President, Generic Products
- Mylan N.V.
Robert Tighe, President, North America
- Rhodes Pharmaceuticals L.P.
Vincent Mancinelli II, President
- Sagent Pharmaceuticals
Peter Kaemmerer, Chief Executive Officer
- Sandoz Inc., A Novartis Division
Carol Lynch, President, Sandoz US and Head of North America
- Taro Pharmaceuticals USA, Inc.
Uday Baldota, Chief Executive Officer
- Teva Pharmaceuticals USA, Inc.
George Keefe, Senior Vice President External Affairs & Public Policy
- Zydus Pharmaceuticals USA, Inc.
Joe Renner, Chairman
A complete list of 2020 AAM Members can be found here.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.